Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients

Biblos-e Archivo/Manakin Repository

Show simple item record Provencio, Mariano Pérez-Callejo, David Torrente, María Martín, Paloma Calvo, Virginia Gutiérrez, Lourdes Franco, Fernando Coronado, María José Cruz-Bermúdez, Juan Luis Martín Ruiz-Valdepeñas, Asunción Cruz-Bermúdez, Alberto Sánchez-Beato, Margarita Romero, Atocha García-Grande, Aránzazu
dc.contributor.other UAM. Departamento de Medicina es_ES 2018-02-09T15:07:07Z 2018-02-09T15:07:07Z 2017-07-31
dc.identifier.citation Oncotarget 8.35 (2017): 59408-59416 en_US
dc.identifier.issn 1949-2553 es_ES
dc.description.abstract Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs). However, the development of liquid biopsies as a diagnostic tool is less developed in these cases. This study investigates the use of CTCs during treatment, together with an extended follow-up to correlate with clinical evolution. Patients and Methods: A total of 13 patients out of a cohort of 212 patients with lung adenocarcinoma, presented ALK rearrangements (6%) confirmed by tumor biopsy. A total of 60 serial blood samples were collected from these patients who were prospectively enrolled in the study. Results: All patients had a positive CTC count at baseline (mean = 3). The median follow-up was 9 months (range 1-17 months). Three patients underwent surgery and their CTC counts decreased after the procedure but still remained detectable. After radiotherapy, 3 cases showed an average decrease of 5 CTCs. A total of 6 patients were treated with ALK inhibitors and a partial response was observed in 3 of them, who also presented decreased CTC counts. The other 3 patients presented primary resistance, and their CTC counts were higher than those obtained prior to progression. Conclusion: We believe that the use of CTCs for dynamic monitoring of NSCLC with ALK rearrangement and to detect disease persistence or recurrence may be a reliable technique. CTC counts may also have potential use to monitor the efficacy of ALK inhibitors, facilitating detection of resistance to treatment en_US
dc.description.sponsorship This study was supported by Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund (grant number: PI16/01818 and PIE14/00064), D. Pérez-Callejo is supported by SEOM-Río-Hortega contract, A Romero is supported by Joan Rodés fellowship (grant number: JR14/00017) and M Sánchez-Beato is supported by Miguel Servet contract (CP11/00018 and CPII16/00024) en_US
dc.format.extent 9 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Impact Journals en_US
dc.relation.ispartof Oncotarget en_US
dc.rights © 2017 Provencio et al. es_ES
dc.subject.other Liquid biopsy en_US
dc.subject.other Non-small-cell lung cancer en_US
dc.subject.other Circulating tumor cells en_US
dc.subject.other ALK-rearrangement en_US
dc.subject.other ALK inhibitors en_US
dc.title Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion es_ES
dc.identifier.doi 10.18632/oncotarget.19722 es_ES
dc.identifier.publicationfirstpage 59408 es_ES
dc.identifier.publicationissue 35 es_ES
dc.identifier.publicationlastpage 59416 es_ES
dc.identifier.publicationvolume 8 es_ES
dc.relation.projectID Gobierno de España. PI16/01818 es_ES
dc.relation.projectID Gobierno de España. PIE14/00064 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Provencio Pulla, Mariano (262376)

Files in this item


This item appears in the following Collection(s)

Show simple item record